These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 739345)

  • 1. Lens opacities in thalassemia.
    Bloomfield SE; Markenson AL; Miller DR; Peterson CM
    J Pediatr Ophthalmol Strabismus; 1978; 15(3):154-6. PubMed ID: 739345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia.
    Cossu P; Toccafondi C; Vardeu F; Sanna G; Frau F; Lobrano R; Cornacchia G; Nucaro A; Bertolino F; Loi A; De Virgiliis S; Cao A
    Eur J Pediatr; 1981 Nov; 137(3):267-71. PubMed ID: 7318837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron chelating therapy in thalassemia: current problems.
    Russo G
    Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract]   [Full Text] [Related]  

  • 4. [The echocardiography in thalassemia major (author's transl)].
    Musumeci S; Schiliro G; Romeo MA; Di Gregorio F; Russo G; Scibilia G
    Pediatr Med Chir; 1981; 3(2-3):219-22. PubMed ID: 6211659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular toxicity of high-dose intravenous desferrioxamine.
    Davies SC; Marcus RE; Hungerford JL; Miller MH; Arden GB; Huehns ER
    Lancet; 1983 Jul; 2(8343):181-4. PubMed ID: 6135026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular findings in beta-thalassemia.
    Sorcinelli R; Sitzia A; Figus A; Lai ME
    Metab Pediatr Syst Ophthalmol (1985); 1990; 13(1):23-5. PubMed ID: 2370833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term administration of desferrioxamine in thalassaemia major.
    Seshadri R; Colebatch JH; Gordon P; Ekert H
    Arch Dis Child; 1974 Aug; 49(8):621-6. PubMed ID: 4278421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The mechanism of cataract formation in persons with beta-thalassemia].
    Popescu C; Siganos D; Zanakis E; Padakis A
    Oftalmologia; 1998; 45(4):10-3. PubMed ID: 10418622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron chelation in transfusion-dependent thalassemia with chronic hepatitis.
    De Virgiliis S; Cossu P; Sanna G; Frau F; Loi E; Lobrano R; Nucaro A; Toccafondi C; Cornacchia G; Loi A; Cao A
    Acta Haematol; 1982; 67(1):49-56. PubMed ID: 6800202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hearing loss and desferrioxamine in homozygous beta-thalassemia.
    Albera R; Pia F; Morra B; Lacilla M; Bianco L; Gabutti V; Piga A
    Audiology; 1988; 27(4):207-14. PubMed ID: 3190562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role and therapeutic use of deferoxamine in iron overload due to thalassemia (author's transl)].
    Lévy G; Bachelot C; Joannard A; Bost M
    Arch Fr Pediatr; 1980 May; 37(5):299-303. PubMed ID: 7469704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monitoring of the harmful effects of iron on the hearts of patients with beta-thalassemia major, using non-invasive cardiological technics].
    Pisano GF; Binaghi F; Putzu ML; Bragotti R; Manconi E; Urgu G; Pitzus F
    Boll Soc Ital Cardiol; 1981; 26(10):1227-33. PubMed ID: 7349145
    [No Abstract]   [Full Text] [Related]  

  • 15. [Audiologic evaluation of patients with thalassemic syndromes treated with desferrioxamine B].
    Gaini RM; Moretti E; Boffa C; Terzoli S; Carnelli V
    Pediatr Med Chir; 1988; 10(5):503-4. PubMed ID: 3241755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.
    Graziano JH; Markenson A; Miller DR; Chang H; Bestak M; Meyers P; Pisciotto P; Rifkind A
    J Pediatr; 1978 Apr; 92(4):648-52. PubMed ID: 633032
    [No Abstract]   [Full Text] [Related]  

  • 17. Ocular changes in patients undergoing long-term desferrioxamine treatment.
    Arden GB; Wonke B; Kennedy C; Huehns ER
    Br J Ophthalmol; 1984 Dec; 68(12):873-7. PubMed ID: 6509007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Desferrioxamine-B in the diagnosis of hemosiderotic states and in the therapy of thalassemia. Apropos of 2 cases].
    De Luca G; Faelli U; Petrussa I
    Minerva Pediatr; 1966 Oct; 18(32):1920-5. PubMed ID: 5993655
    [No Abstract]   [Full Text] [Related]  

  • 19. Reduction of iron overload in thalassemia.
    Piomelli S; Graziano J
    Birth Defects Orig Artic Ser; 1982; 18(7):339-46. PubMed ID: 7159742
    [No Abstract]   [Full Text] [Related]  

  • 20. [Thalassemia major: chelating therapy with deferoxamine].
    Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
    Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.